The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency

Diabetes, Obesity & Metabolism
P C Y TongJ C N Chan

Abstract

The renoprotective effect of angiotensin II antagonists has been demonstrated in type 2 diabetic patients with nephropathy but similar data on angiotensin-converting enzyme (ACE) inhibitors are limited. We examined the efficacy and tolerability of fosinopril, an ACE inhibitor with dual hepatic and renal clearance, in 38 type 2 diabetic patients with moderate renal impairment (plasma creatinine 130-300 micromol/l) over a 2-year period. This was a single-centre, randomized, double-blinded, placebo-controlled trial comparing fosinopril 20 mg daily vs. placebo in addition to conventional antihypertensive treatment over a 2-year period. The primary endpoints were the rate of change and the percentage change in both 24-h urinary albumin excretion (UAE) and creatinine clearance (CrCl). The mean age of the patients was 65 +/- 6 years (range 47-76 years, median 66 years) and plasma creatinine 190 +/- 49 micromol/l. For similar blood pressure control, the percentage change of UAE in patients with microalbuminuria was greater in the fosinopril than the placebo group (-24.2 +/- 28.8 vs. 11.6 +/- 42.1%, p = 0.003 after adjustment for baseline covariates). In the fosinopril group, the rate of change of endogenous CrCl was slower than the pla...Continue Reading

References

Jun 1, 1997·Clinical Pharmacokinetics·H ShionoiriI Takasaki
Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·E RitzS Halimi
Sep 8, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G L BakrisJ Sowers
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Apr 30, 2002·Diabetes Care·Teresa Yuk Hwa WongFernand Mac-Moune Lai
Mar 13, 2003·Kidney International·William F KeaneUNKNOWN RENAAL Study Investigators

❮ Previous
Next ❯

Citations

Mar 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ausilia MaioneGiovanni F M Strippoli
Jul 21, 2012·Diabetes & Metabolic Syndrome·Weiwei Zheng, Ling Chen
Nov 26, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xinfang XieHaiyan Wang
Apr 1, 2008·Journal of Evaluation in Clinical Practice·Samina Khan, Chester A Amedia
May 6, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·UNKNOWN Guideline development group
Nov 7, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ionut NistorAdrian Covic
Oct 2, 2020·Kidney International·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group
Oct 18, 2007·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.